Condition

PDAC clinical trials and research

• 16Clinical trials
• 71NIH research projects
• 27Countries

Newest PDAC clinical trials

All recruiting trials (16)

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

• Telisotuzumab adizutecan with FOLFOX versus standard care in first-line metastatic pancreatic cancer

  This study tests whether adding telisotuzumab adizutecan to FOLFOX helps adults with unresectable, metastatic pancreatic cancer compare to standard treatment.

  Recruiting at 22 sites Phase 2/3 AbbVie · New Haven, Connecticut and 21 other locations · NCT07490301

• IN10018 plus RNK08954 for KRASG12D-positive advanced solid tumors

  This trial will test whether combining IN10018 with RNK08954 can shrink tumors or control disease in people with KRASG12D-mutated locally advanced or metastatic solid tumors, with enrollment focused on pancreatic cancer.

  Recruiting Phase 1/2 InxMed (Shanghai) Co., Ltd. · Beijing, Beijing Municipality and 13 other locations · NCT07441174

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• GFH375 combined with cetuximab or chemotherapy for KRAS G12D–mutant solid tumors

  This tests whether adding GFH375 to cetuximab or to standard chemotherapy helps people with advanced solid tumors that have a KRAS G12D mutation.

  Recruiting Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Beijing, Beijing Municipality and 3 other locations · NCT07259590

• Daraxonrasib after surgery for resected pancreatic ductal adenocarcinoma (PDAC)

  This trial tests whether taking daraxonrasib after surgery can help prevent cancer from coming back in adults with resected PDAC who completed perioperative chemotherapy.

  Recruiting at 85 sites Phase 3 Revolution Medicines, Inc. · Birmingham, Alabama and 85 other locations · NCT07252232

• Engineered T cells targeting KRAS mutations for advanced pancreatic cancer

  This trial tests engineered T cells designed to target specific KRAS mutations in adults with metastatic or locally advanced pancreatic ductal adenocarcinoma who have received standard first-line therapy.

  Recruiting at 8 sites Phase 1/2 Anocca AB · Copenhagen and 9 other locations · NCT07145450

• TNG462 combined with RAS inhibitors or chemotherapy for MTAP‑loss pancreatic and RAS‑mutant lung cancer

  This trial will test whether taking oral TNG462 together with RAS inhibitors or standard chemotherapy is safe and helps people with MTAP‑loss pancreatic cancer or RAS‑mutant non‑small cell lung cancer.

  Recruiting at 18 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 17 other locations · NCT06922591

• Investigating ADCE-T02 for advanced solid tumors

  This study is testing a new drug called ADCE-T02 to see if it can safely help people with advanced solid tumors that can't be surgically removed.

  Recruiting at 14 sites Phase 1 Adcendo ApS · Rogers, Arkansas and 13 other locations · NCT06597721

• Assessing Prognosis in Pancreatic Cancer Using Lewis Antigen and CA19-9 Tests

  This study is testing if combining Lewis antigen and CA19-9 tests can help doctors better understand the outlook for patients with pancreatic cancer.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06515587

• Evaluating RAS(ON) Inhibitors for Gastrointestinal Solid Tumors

  This study is testing new RAS(ON) inhibitors combined with standard treatments to see if they can help people with certain types of gastrointestinal cancers that have RAS mutations.

  Recruiting at 32 sites Phase 1/2 Revolution Medicines, Inc. · Chandler, Arizona and 31 other locations · NCT06445062

• Registry for patients at high risk for pancreatic cancer

  This study is creating a registry for people at high risk of pancreatic cancer to see if new tests can help catch the disease early.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06151223

• Screening for pancreatic cancer in high-risk individuals

  This study is testing if combining blood tests and symptom checks with regular screenings can help find pancreatic cancer earlier in people who are at higher risk because of their genetics.

  Recruiting Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06122896

NIH-funded research (newest 40 of 71)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Targeting epigenomic regulators to assault pancreatic cancer replication stress

  This research tests a new way to treat pancreatic cancer by blocking key epigenetic regulators during DNA replication to make cancer cells less able to cope with replication stress.

  NIH research Mayo Clinic Arizona · Scottsdale, United States · NIH-11522481

• Neoantigen vaccines in pancreatic cancer: overcoming resistance to improve immune responses

  This grant supports testing advanced neoantigen vaccines in pancreatic cancer to boost patients' immune responses and potentially improve outcomes.

  NIH research Washington University · Saint Louis, United States · NIH-11419673

• CD11b-activating drug to make pancreatic cancer respond to immunotherapy

  A study to see if a CD11b-activating drug (GB1275) can help pancreatic cancer patients respond better to immunotherapy when combined with standard chemotherapy and PD-1 blockers.

  NIH research Washington University · Saint Louis, United States · NIH-11419672

• Targeting autophagy to treat KRAS-mutant pancreatic cancer

  This grant explores using approved drugs to block autophagy in KRAS-mutant pancreatic cancer to improve treatment outcomes.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11416750

• Reprogramming PDAC stroma by targeting blood clotting in the tumor environment

  A cancer research grant aimed at turning the tough, fibrous pancreatic cancer environment into one that helps treatments work better and supports the body’s immune response.

  NIH research University of Illinois at Urbana-Champaign · Champaign, United States · NIH-11416346

• Understanding paracrine signals in pancreatic cancer to improve drug delivery

  A patient-focused look at how the tumor’s signaling networks affect treatment delivery in pancreatic cancer and how targeting these networks could help therapies reach tumors more effectively.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11411417

• Collagen and PDAC: how the tumor’s surrounding support system shapes growth and immunity

  This grant looks at how collagen in pancreatic cancer interacts with tumor cells and the immune system to influence disease progression.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11408793

• Metabolic vulnerability in pancreatic cancer cachexia linked to fat metabolism

  This grant explores why people with pancreatic cancer lose weight and fat tissue and how fat metabolism affects their health and recovery.

  NIH research Oregon Health & Science University · Portland, United States · NIH-11404966

• Antidepressants as a potential weapon against pancreatic cancer spread

  This project tests whether commonly used antidepressants can help reduce spread and improve treatment response in pancreatic cancer patients.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11396327

• PDAC subtypes and racial disparities in pancreatic cancer

  This project looks at how pancreatic cancer behaves differently across racial groups and aims to uncover molecular patterns that could lead to better, tailored treatments.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11395453

• Targeting Perp in pancreatic cancer and its muscle wasting

  This NIH grant explores a gene called Perp as a potential target to slow pancreatic cancer growth and reduce cachexia in patients.

  NIH research University of North Carolina Charlotte · Charlotte, United States · NIH-11394547

• Tumor-Selective Bacterial Therapy to Rebuild the Immune Attack on Pancreatic Cancer

  A new bacterial therapy is being tested to target pancreatic cancer, help break down its protective environment, and boost the body’s own immune response.

  NIH research University of Missouri-Columbia · Columbia, United States · NIH-11391856

• Genetic and gene-activity differences linked to pancreatic cancer disparities

  This project looks at DNA changes and gene activity in pancreatic tumors to find differences that may help explain why African American patients often have worse outcomes.

  NIH research University of Iowa · Iowa City, United States · NIH-11376128

• Lipogenesis-Driven Resistance in pancreatic cancer and how to overcome it

  A small grant is testing whether turning up fat production in pancreatic cancer helps tumors survive chemotherapy and radiation, and whether blocking this fat production could make treatments work better.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11363958

• Blocking Perp to slow pancreatic cancer and cancer-related muscle wasting

  This project will test whether lowering a protein called Perp can shrink pancreatic tumors and help people with pancreatic cancer who are losing weight and muscle.

  NIH research University of North Carolina Charlotte · Charlotte, United States · NIH-11363734

• Combination therapy targeting tumor and surrounding stroma in pancreatic cancer

  Aims to improve treatment for pancreatic cancer by delivering a targeted therapy together with a agent that changes the tumor environment to help drugs work better.

  NIH research St. John's University · Queens, United States · NIH-11355568

• Targeting how racial differences shape PDAC biology to reduce disparities

  This grant seeks to understand why pancreatic cancer behaves differently among Black patients and to identify new ways to tailor treatments for those disparities.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-11354410

• Imaging and targeted nanoparticle therapy for pancreatic cancer-related weight loss

  Using advanced imaging and nanoparticles that deliver gene-silencing medicine to try to stop or reverse severe weight loss in people with pancreatic cancer.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11307168

• FLASH proton radiotherapy for pancreatic cancer that spares the intestines

  This project compares ultra-fast 'FLASH' proton radiotherapy with standard proton therapy to see if it controls pancreatic tumors while reducing damage to the intestines for people with pancreatic cancer.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11298923

• Nanoparticles that soften pancreatic cancer scar tissue to boost chemo and immune therapy

  This project uses tiny nanoparticles carrying RNA to change the scar-like tissue around pancreatic tumors so chemotherapy and immune treatments can reach and kill cancer cells more effectively for people with pancreatic ductal adenocarcinoma.

  NIH research University of Missouri Kansas City · Kansas City, United States · NIH-11296927

• Blocking fibroblast-made nutrients that feed pancreatic cancer

  This work looks at whether stopping support from tumor fibroblasts for a specific nutrient pathway can slow pancreatic ductal adenocarcinoma (PDAC).

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11294161

• PDAC immunotherapy using attenuated bacteria plus low-dose gemcitabine

  A first-in-human study tests a new cancer immunotherapy that uses weakened bacteria to deliver immune-stimulating components to pancreatic cancer in combination with a low dose of gemcitabine.

  NIH research Loki Therapeutics, INC · Sa, UNITED STATES · NIH-11247611

• How different KRAS mutations drive pancreatic cancer and point to new treatment targets

  This project studies how specific changes in the KRAS gene cause pancreatic ductal adenocarcinoma and aims to reveal weaknesses that could become new treatment targets for people with this cancer.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11237619

• A virus-based therapy targeting pancreatic cancer

  This project develops redesigned cancer-killing adenoviruses that can be given through the bloodstream to treat people with advanced pancreatic ductal adenocarcinoma.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11233150

• How collagen affects cancer growth and immune response in pancreatic cancer

  This study is looking at how collagen affects the way pancreatic cancer cells behave and how the body’s immune system responds, using a special model that simulates the tumor environment to find new ways to treat patients with pancreatic cancer.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11229316

• Investigating how a specific protein affects pancreatic cancer growth and spread

  This study is looking at a protein called RCC1 to see how it affects pancreatic cancer cells, with the hope that understanding its role could help develop new treatments for patients facing this tough disease.

  NIH research Wayne State University · Detroit, United States · NIH-11228868

• Blocking cancer cell recycling in KRAS-mutant pancreatic cancer

  This project is trying to combine drugs that block cancer growth signals with hydroxychloroquine to help people with KRAS-mutant pancreatic cancer respond better to treatment.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11196737

• Resistance to neoantigen vaccines in pancreatic cancer

  Optimized neoantigen vaccines aim to boost tumor-specific T cells in people with pancreatic cancer.

  NIH research Washington University · Saint Louis, United States · NIH-11187265

• Using a new drug to help pancreatic cancer respond to immunotherapy

  This project gives a drug called GB1275 together with chemotherapy and a PD-1 immunotherapy to people with metastatic pancreatic cancer to boost the immune attack on tumors.

  NIH research Washington University · Saint Louis, United States · NIH-11187264

• Reprogramming immune cells to help fight pancreatic cancer

  This work aims to restore and activate key immune cells called dendritic cells so people with pancreatic cancer respond better to radiation and immune treatments.

  NIH research Washington University · Saint Louis, United States · NIH-11187150

• Changing pancreatic cancer's scar-like tissue to make treatments work better

  This project tests therapies that block blood-clotting signals in pancreatic cancer to help chemotherapy and immunotherapy work better for people with pancreatic ductal adenocarcinoma.

  NIH research University of Illinois at Urbana-Champaign · Champaign, United States · NIH-11181324

• Why pancreatic cancer causes rapid fat and muscle loss

  This project tests whether abnormal fat burning in people with pancreatic cancer causes the severe weight and muscle loss called cachexia and whether fixing that metabolism could help patients.

  NIH research Oregon Health & Science University · Portland, United States · NIH-11178485

• AI to find early signs of pancreatic cancer on routine CT scans

  Uses artificial intelligence to look at routine abdominal CT scans and medical information to find people likely to develop pancreatic cancer within three years.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11172502

• How pancreatic tumor genes shape immune cells and response to macrophage therapies

  This project looks at whether differences in tumor genes change the immune environment in pancreatic cancer and whether treatments that target macrophages might help certain patients.

  NIH research Stanford University · Stanford, United States · NIH-11171450

• Investigating ways to reverse weight loss caused by pancreatic cancer.

  This study is looking at ways to help people with pancreatic cancer who are experiencing severe weight loss by using special techniques to target and change how their bodies process certain nutrients, with the hope of improving their health and well-being.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11167154

• Blocking harmful cell-to-cell signals in pancreatic cancer

  This project looks for and targets the signaling 'conversations' between pancreatic tumors and nearby support cells to help treatments work better for people with pancreatic ductal adenocarcinoma.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11163415

• How stromal IL-6/STAT3 signaling affects pancreatic cancer and cancer-related weight loss

  Looking at whether a cell-signaling pathway called IL-6/STAT3 in the tumor's supportive stromal cells drives pancreatic cancer growth and the severe muscle and fat wasting many patients experience.

  NIH research Medical University of South Carolina · Charleston, United States · NIH-11144581

• Different molecular types of pancreatic cancer may explain worse outcomes in Black patients

  This project looks at whether distinct molecular subtypes of pancreatic cancer, especially in Black patients, help explain higher rates and shorter survival.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11128352

• Exploring new treatments for pancreatic cancer using advanced models

  This study is looking at a new protein that could help create better treatments for pancreatic cancer by figuring out how it affects cancer cells and their ability to resist drugs, so we can target the cancer more effectively while leaving healthy cells alone.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-11091485

• Combining targeted therapy with a stroma-modulating agent for pancreatic cancer

  This study is exploring a new way to treat pancreatic cancer by using a special combination of drugs that not only attack the cancer cells but also help the surrounding tissue, making it easier for the medicine to work better, and patients may have the chance to participate in testing how safe and effective this treatm

  NIH research St. John's University · Queens, United States · NIH-11083663

Related topics

Quick answers

How many PDAC clinical trials are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 27 countries. The most sites are in United States (12 trials), United Kingdom (5 trials), Australia (4 trials), Germany (4 trials), China (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 1/2: 5, Phase 1: 2, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →